BG103106A - Trovafloxacin mesilate tablets - Google Patents

Trovafloxacin mesilate tablets

Info

Publication number
BG103106A
BG103106A BG103106A BG10310699A BG103106A BG 103106 A BG103106 A BG 103106A BG 103106 A BG103106 A BG 103106A BG 10310699 A BG10310699 A BG 10310699A BG 103106 A BG103106 A BG 103106A
Authority
BG
Bulgaria
Prior art keywords
tablets
trovafloxacin mesilate
mesilate
trovafloxacin
compositions
Prior art date
Application number
BG103106A
Other languages
Bulgarian (bg)
English (en)
Inventor
Alton JOHNSON
Christopher SINKO
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG103106A publication Critical patent/BG103106A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG103106A 1998-01-21 1999-01-21 Trovafloxacin mesilate tablets BG103106A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7201398P 1998-01-21 1998-01-21

Publications (1)

Publication Number Publication Date
BG103106A true BG103106A (en) 1999-08-31

Family

ID=22105016

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103106A BG103106A (en) 1998-01-21 1999-01-21 Trovafloxacin mesilate tablets

Country Status (34)

Country Link
US (1) US6187341B1 (fr)
EP (1) EP0930068A3 (fr)
JP (1) JPH11269072A (fr)
KR (1) KR100314977B1 (fr)
CN (1) CN1227743A (fr)
AP (1) AP1094A (fr)
AR (1) AR012780A1 (fr)
AU (1) AU758381B2 (fr)
BG (1) BG103106A (fr)
BR (1) BR9900116A (fr)
CA (1) CA2259698C (fr)
CO (1) CO4810225A1 (fr)
DZ (1) DZ2712A1 (fr)
EA (1) EA003247B1 (fr)
GT (1) GT199900004A (fr)
HR (1) HRP990023A2 (fr)
HU (1) HUP9900154A3 (fr)
ID (1) ID23735A (fr)
IL (1) IL128051A0 (fr)
IS (1) IS4947A (fr)
MA (1) MA24747A1 (fr)
NO (1) NO990243L (fr)
NZ (1) NZ333838A (fr)
OA (1) OA10958A (fr)
PA (1) PA8466701A1 (fr)
PE (1) PE20000169A1 (fr)
PL (1) PL330981A1 (fr)
SG (1) SG70666A1 (fr)
SK (1) SK4299A3 (fr)
TN (1) TNSN99007A1 (fr)
TR (1) TR199900089A2 (fr)
TW (1) TW518224B (fr)
YU (1) YU2399A (fr)
ZA (1) ZA99393B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE279193T1 (de) * 1998-11-10 2004-10-15 Bayer Healthcare Ag Pharmazeutische zubereitung von moxifloxacin
CA2382834A1 (fr) * 1999-09-20 2001-03-29 Alza Corporation Procede destine a reduire la transformation polymorphique d'un medicament
AR025976A1 (es) * 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
FR2808441B1 (fr) * 2000-05-04 2004-06-18 Oreal Utilisation de fibres dans une composition de soin ou de maquillage pour matifier la peau
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
CA2444597A1 (fr) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Inhibiteurs de fab i
EP1396263A1 (fr) * 2002-08-09 2004-03-10 Warner-Lambert Company Compositions d'enrobage pour tablettes et caplets
CA2508792C (fr) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Composes heterocycliques, procedes de production de ceux-ci et utilisation de ceux-ci dans un traitement
CN100415284C (zh) * 2002-12-30 2008-09-03 毛友昌 六味木香片的制备方法
WO2004082586A2 (fr) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Compositions comportant plusieurs agents antibiotiques, et leurs procedes de mise en oeuvre
ES2297067T3 (es) * 2003-03-19 2008-05-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Composiciones farmaceuticas no higroscopicas que contienen acidos quinolinacarboxilicos de hidratados.
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20050019397A1 (en) * 2003-07-23 2005-01-27 Jacobs Richard L. Cellulosic fiber containing composition
CA2568914C (fr) 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Agents therapeutiques, et methodes de fabrication et d'utilisation
AU2005295482B2 (en) * 2004-10-15 2011-03-31 Supernus Pharmaceuticals Inc. Less abusable pharmaceutical preparations
EP1973902A2 (fr) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. Agents therapeutiques et ses procédés de fabrication et d utilisation
EP2687533B1 (fr) 2006-07-20 2017-07-19 Debiopharm International SA Dérivés d'acrylamide en tant qu'inhibiteurs de FAB I
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm
JP2025529185A (ja) * 2022-08-30 2025-09-04 パンネックス セラピューティクス インコーポレイテッド パネキシン-1調節剤及びパネキシン-1が関与する疾患の治療方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
US4957554A (en) 1989-08-16 1990-09-18 Minnesota Mining And Manufacturing Company Dimensionally-controlled ceramics
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
NZ312199A (en) * 1995-08-29 1999-06-29 Pfizer Zwitterionic forms of trovafloxacin

Also Published As

Publication number Publication date
ID23735A (id) 2000-05-11
DZ2712A1 (fr) 2003-09-01
PA8466701A1 (es) 2000-09-29
SG70666A1 (en) 2000-02-22
KR100314977B1 (ko) 2001-11-24
JPH11269072A (ja) 1999-10-05
HRP990023A2 (en) 1999-08-31
HUP9900154A3 (en) 2000-12-28
AU1217399A (en) 1999-08-12
CO4810225A1 (es) 1999-06-30
US6187341B1 (en) 2001-02-13
CA2259698C (fr) 2003-04-15
IS4947A (is) 1999-07-22
AR012780A1 (es) 2000-11-08
OA10958A (en) 2001-10-31
HUP9900154A2 (hu) 1999-09-28
AP9901443A0 (en) 1999-03-31
BR9900116A (pt) 2000-05-02
KR19990068014A (ko) 1999-08-25
EA199900046A3 (ru) 1999-12-29
GT199900004A (es) 2000-07-08
CA2259698A1 (fr) 1999-07-21
AU758381B2 (en) 2003-03-20
PE20000169A1 (es) 2000-03-10
EP0930068A2 (fr) 1999-07-21
EA199900046A2 (ru) 1999-08-26
TR199900089A3 (tr) 1999-10-21
AP1094A (en) 2002-08-19
NZ333838A (en) 2000-03-27
TR199900089A2 (xx) 1999-10-21
HU9900154D0 (en) 1999-03-29
PL330981A1 (en) 1999-08-02
IL128051A0 (en) 1999-11-30
EA003247B1 (ru) 2003-02-27
CN1227743A (zh) 1999-09-08
NO990243L (no) 1999-07-22
ZA99393B (en) 2000-07-21
SK4299A3 (en) 2000-06-12
YU2399A (sh) 2002-06-19
TW518224B (en) 2003-01-21
NO990243D0 (no) 1999-01-20
TNSN99007A1 (fr) 2005-11-10
EP0930068A3 (fr) 1999-12-22
MA24747A1 (fr) 1999-10-01

Similar Documents

Publication Publication Date Title
YU2399A (sh) Tableta trovafloksacin mezilata
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
BG103413A (en) Derivatives of sulphinic acid, their production and application
WO2002010137A3 (fr) Derives d'indazole utilises comme inhibiteurs de jnk et compositions et methodes associees a ceux-ci
HK1039110A1 (zh) 以新颖的合成物及组分作为蛋白酶抑制剂
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
GEP20033000B (en) 2-Substituted-1-Piperidyl Benzimidazole Compounds as ORL1-Receptor Agonists
DE3474631D1 (en) N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
BG106013A (en) New compounds and compositions as protease inhibitors
NZ520624A (en) 1,2,3,4-tetrahydroisoquinoline derivatives
IS7545A (is) 7-Arýl-3,9-díasabísýkló(3.3.1)nón-6-en afleiður og notkun þeirra sem renín hindra í meðferð á háþrýstingi, hjarta- og æða- eða nýrna sjúkdómum
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
CA2343236A1 (fr) Derives de 4,4-biarylpiperidine
IL114599A0 (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containing them
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
FI970147A0 (fi) Triatsoliyhdisteitä ja niiden käyttö dopamiini-D3-ligandeina
TW200514772A (en) Novel tetrahydropyridine derivatives
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
CA2378428A1 (fr) Utilisation d'antagonistes de cgrp et d'inhibiteurs de secretion cgrp servant a lutter contre les bouffees de chaleur de la menopause
AU5915100A (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
CA2266759A1 (fr) Derives 3-mercaptoacetylamino-1,5-substitue-2-oxo-azepane, utilises comme inhibiteurs de metalloproteinase matrice
CA2378834A1 (fr) Pyrazinones, compositions contenant ces composes
PT1427417E (pt) Derivados de 6, 7-di-hidroxitetra-hidroisoquinolina substituída em 3 para utilização como agentes antibacterianos
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.